The Sphingosine-1-Phosphate Analogue FTY720 Impairs Mucosal Immunity and Clearance of the Enteric Pathogen Citrobacter rodentium

IL-6-Dependent Mucosal Protection Prevents Establishment of a Microbial Niche for Attaching/Effacing Lesion-Forming Enteric Bacterial Pathogens

(2014) S. M. Dann et al.   JOURNAL OF IMMUNOLOGY

The Pathogenicity of an EntericCitrobacter rodentiumInfection Is Enhanced by Deficiencies in the Antioxidants Selenium and Vitamin E

(2011) Allen D. Smith et al.   INFECTION AND IMMUNITY

FTY720 Blocks Egress of T Cells in Part by Abrogation of Their Adhesion on the Lymph Node Sinus

(2011) L. Zhi et al.   JOURNAL OF IMMUNOLOGY

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

(2011) M. Mehling et al.   NEUROLOGY

Use of bioluminescence imaging to track neutrophil migration and its inhibition in experimental colitis

(2010) C. T. Murphy et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Fingolimod for relapsing multiple sclerosis: an update

(2010) Alejandro Horga et al.   EXPERT OPINION ON PHARMACOTHERAPY

Gamma Interferon Produced by Antigen-Specific CD4+ T Cells Regulates the Mucosal Immune Responses to Citrobacter rodentium Infection

(2010) H. Shiomi et al.   INFECTION AND IMMUNITY

Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics

(2010) Shobha Thangada et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Technical Advance: Function and efficacy of an α4 -integrin antagonist using bioluminescence imaging to detect leukocyte trafficking in murine experimental colitis

(2010) Carola T. Murphy et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

(2010) Volker Brinkmann et al.   NATURE REVIEWS DRUG DISCOVERY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

B Lymphocytes Exit Lymph Nodes through Cortical Lymphatic Sinusoids by a Mechanism Independent of Sphingosine-1-Phosphate-Mediated Chemotaxis

(2009) Rajesh K. Sinha et al.   IMMUNITY

Differential Roles of Interleukin-17A and -17F in Host Defense against Mucoepithelial Bacterial Infection and Allergic Responses

(2009) Harumichi Ishigame et al.   IMMUNITY

Evaluation of the lymphocyte trafficking drug FTY720 in SHIVSF162P3-infected rhesus macaques

(2009) E. N. Kersh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Sphingosine 1-Phosphate Receptor Agonist FTY720 Potently Inhibits Regulatory T Cell Proliferation In Vitro and In Vivo

(2009) A. M. Wolf et al.   JOURNAL OF IMMUNOLOGY

CXCR2-Dependent Mucosal Neutrophil Influx Protects against Colitis-Associated Diarrhea Caused by an Attaching/Effacing Lesion-Forming Bacterial Pathogen

(2009) M. E. Spehlmann et al.   JOURNAL OF IMMUNOLOGY

Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice

(2008) Reiko Ito et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Infections cast cloud over Novartis' MS therapy

(2008) Ken Garber   NATURE BIOTECHNOLOGY

Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens

(2008) Yan Zheng et al.   NATURE MEDICINE